Melinta Therapeutics Reports Top-Line Results Showing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration

NEW HAVEN, Conn, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced top-line results of a Phase 1 clinical study that demonstrated that the administration of single doses of 450 mg oral and 300 mg intravenous (I.V.) formulations of delafloxacin provide similar blood exposure. Delafloxacin is an investigational fluoroquinolone under development for acute bacterial skin and skin structure infections and uncomplicated gonorrhea.

In this study of 56 healthy adults, the oral formulation provided total comparable exposure (area under the curve-AUC) compared to I.V. administration, meeting pre-defined criteria. Peak blood levels were lower with the oral compared with I.V. dosing. Since antimicrobial activity for delafloxacin is correlated with AUC, these data support "step-down" from intravenous to oral dosing. Single doses in both groups were well tolerated.

Complete results from these studies will be presented at the 54th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an American Society for Microbiology meeting. ICAAC is being held September 5-9, 2014 at the Washington, DC Convention Center.

About Melinta Therapeutics

Melinta Therapeutics, Inc. is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI) and uncomplicated gonorrhea. Delafloxacin has been designated a qualified infectious disease product (QIDP) for ABSSSI, uncomplicated gonorrhea and community-acquired bacterial pneumonia by the U.S. Food and Drug Administration. A key initiative at Melinta is to develop, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the drug-resistant ESKAPE pathogens known to cause serious hospital infections. Melinta Therapeutics is privately held and backed by lead investor Vatera Healthcare Partners among other private investors. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL.

For more information, visit www.melinta.com .

Melinta Therapeutics Kathy Powell Media Contact Aline Schimmel

Scroll down for more posts ▼

Top 10 Most Recent News Articles

When Families Should Consider Life Insurance Plans

Updated Category News Views 2

Let’s talk about why life insurance isn’t just for those walking around with gray hair. K.D. the Insurance Queen from Centennial, Colorado, dishes out the clearest advice on when and why families ought to have it in their arsenal. A New Mindset on Life Insurance Some folks out there think life insurance is something you ponder in your twilight years. But here’s the...

Continue Reading
Greenland Energy Board Reshuffle: McIllree Exits

Updated Category News Views 9

A Change in Greenland Energy's Lineup Well, folks, the wheel keeps turning at Greenland Energy Company (NASDAQ:GLND). Roderick McIllree has decided to step off the Board of Directors' carousel, effective immediately. And nope, there wasn't a classic showdown or any disagreement on the table. This exit is as drama-free as they come—just him stepping aside, leaving the...

Continue Reading
Tampa General's Tech Triumphs in Healthcare Innovation

Updated Category News Views 0

Spotlight on Tampa General's Technological Edge Wow, just when you think you've seen it all in the healthcare sector, here comes Tampa General Hospital (TGH) shaking things up again. Making waves by earning a spot among the "World's Best Smart Hospitals for 2027" by Newsweek and Statista, TGH's proving that tech-savvy isn't just for Silicon Valley startups. Folks, being...

Continue Reading
Unicycive Faces Legal Heat: Investors Eye Key Deadline

Updated Category News Views 5

What Went Wrong with Unicycive? Unicycive Therapeutics, Inc., a player in the biotech space, finds itself embroiled in a legal quagmire. A class action lawsuit is hovering over NASDAQ:UNCY, spurred by allegations of the company's slip-ups in manufacturing oversight. Investors are ticked off, understandably, as the lawsuit zeroes in on failures to resolve FDA-cited issues....

Continue Reading
College Athletics Needs a New Business Revolution

Updated Category News Views 3

Wake Up Call for College Athletics Here's a heads-up—college sports aren't just about cheering fans and game-day jerseys anymore. It's high time universities start thinking of athletics as businesses, blending the thrill of game day with the realities of financial statements. Michael Schreiber rang this bell loud and clear on the 'Disruption Interruption' podcast,...

Continue Reading
French Florist Blossoms in Los Gatos This October

Updated Category News Views 3

A New Floral Journey Blooms in Los Gatos October's shaping up to be a vibrant month for Los Gatos, as a slice of French elegance arrives courtesy of Anhelina Baftalovska. She's not just bringing flowers; she's introducing a unique blend of life passions and entrepreneurial spirit to the community. Let's dig into this delightful story of blooms and business. A Ukrainian's...

Continue Reading
Corra Group Enhances Hiring with Digital I-9 Services

Updated Category News Views 4

The Changing Landscape of Employment Verification Employment verification is no longer a mere formality with a paper form. Now, it’s a digital jungle, where missing a deadline isn't just a slap on the wrist, but a compliance nightmare. In steps Corra Group, bringing electronic I-9 tools to the frontlines, geared to help employers juggle the mess of forms, deadlines, and...

Continue Reading
Venture Dock Fosters Global Startup Ecosystems

Updated Category News Views 2

Venture Dock Connects the Global Startup Dots When it comes down to bridging the gap between promising innovation and commercial success, you'd be hard-pressed to find a better player than Venture Dock. In a world filled with buzzwords and fluff, these guys are socketed deep in the guts of genuine startup development — and they're making waves with their recent...

Continue Reading
Ecopetrol Ushers New Executive Leadership for Transition

Updated Category News Views 5

New Blood Steering the Energy Transition Let's crack open the vault on Ecopetrol's recent maneuver: Armando José Cuello Navarro is stepping up as the new Executive Vice President of Energy Transition. It's like handing the wheel to a seasoned driver in a storm—this guy’s got the chops to navigate Colombia's energy maze. Cuello's resume reads like a textbook on energy...

Continue Reading
Visteon Reports Q3 2026 Results with Mixed Signals

Updated Category News Views 1

Visteon's Q3 2026 Financial Performance: Insights and Implications You'd think by now that anything to do with supply chain hiccups wouldn’t surprise me, but Visteon Corporation’s recent third quarter results got my gears grinding yet again. Here's the scoop: Visteon pulled in $970 million in sales, strutting around with a 10% growth-over-market. Their resilience...

Continue Reading

Top 5 Most Recently Viewed Articles

Application Modernization Services Market Growth Insights

Updated Category News Views 133

Understanding the Application Modernization Services Market The Application Modernization Services Market has seen remarkable growth, reflecting the need for organizations to revitalize their outdated systems. As technology continues to evolve, the motivation for companies to embrace innovation and upgrade their applications has never been more pressing. By revitalizing...

Continue Reading
Expert Forecasts Bitcoin's Bright Future and New Support Levels

Updated Category News Views 971

Bitcoin Nears a Defining Moment Bitcoin is currently trading at approximately $115,000, and significant attention is focused on an upcoming date that may influence its trajectory well into the future. Traders are eagerly anticipating developments as the crypto market continues to evolve. The Significance of September 21 Predictive Analysis by Timothy Peterson Renowned...

Continue Reading
Circus SE Unveils Ambitious 2025 Strategy Empowering Physical AI

Updated Category News Views 274

Circus SE Unveils Ambitious 2025 Strategy Empowering Physical AI Circus SE (XETRA: CA1), recognized globally for its pioneering role in Physical AI applications, has shared an insightful view into its strategy for 2025. This plan positions Circus at the forefront of the evolving landscape of AI, particularly within labor-intensive sectors like food service. With...

Continue Reading
Bloomberg Tax Workpapers' Groundbreaking AI Enhancements Earn Gold

Updated Category News Views 177

Bloomberg Tax Workpapers' Recognition at Business Awards Today, Bloomberg Tax & Accounting proudly announced an esteemed recognition: their AI enhancements to Bloomberg Tax Workpapers have won a Gold Stevie Award in the Financial Management Solution category. This accolade was presented during the 23rd Annual American Business Awards, highlighting the commitment to...

Continue Reading
Important Securities Class Action Update for Wolfspeed Investors

Updated Category News Views 225

Crucial Information for Wolfspeed, Inc. Investors The law firm Kessler Topaz Meltzer & Check, LLP has issued an important update concerning a securities class action lawsuit against Wolfspeed, Inc. (NYSE: WOLF). Investors who purchased or acquired shares of Wolfspeed securities during a specified period may be eligible to participate in the case. Understanding the Class...

Continue Reading